Walvaxysb88会员登录网址易胜博最新地址

  • Our Company
  • Our Journey
  • Contact Us
  • Value of Vaccines
  • Products List
  • ysb88会员登录网址-易胜博登陆-易胜博最新地址
  • Distribution
  • R&D Platform
  • Pipeline
  • Investors
  • Media
  • Collaborations
  • Career
  • Responsibility
  • Our Company
  • Our Journey
  • Contact Us
  • Value of Vaccines
  • Products List
  • ysb88会员登录网址-易胜博登陆-易胜博最新地址
  • Distribution
  • R&D Platform
  • Pipeline
  • Investors
  • Media
  • Collaborations
  • Career
  • Responsibility
  • CN
    EN

    Manufacturing Center Locations

    Till date, Walvax has three manufacturing centers in Yuxi City, Yunnan, Daxing District, Beijing and Taizhou City, Jiangsu, respectively.

    1 2 3
  • 1. Yuxi Manufacturing Center

    - ysb88会员登录网址-易胜博登陆-易胜博最新地址 of all the marketed products, SARS-CoV-2 mRNA vaccine and HPV vaccines
    - China's first mRNA vaccine manufacturing center
    - 130,000 square meters of floor space
    - About 190 million doses of annual capacity

  • 2. Beijing Manufacturing Center

    - ysb88会员登录网址-易胜博登陆-易胜博最新地址 of adenoviral vector based SARS-CoV-2 vaccine
    - New plant with more than 10,000 square meters under construction

  • 3. Taizhou Manufacturing Center

    - ysb88会员登录网址-易胜博登陆-易胜博最新地址 of Influenza Vaccine
    - More than 20,000 square meters of plant space

  • Industry Leading Manufacturing Capacity

    High Quality

    Product Quality: 

    - We meet international product quality standards like WHO, EU etc. and some standards are higher than EU.

     


    Manufacturing Base: 

    - Construction standards benchmark generally-accepted regulatory requirements set by ICH, WHO, EMA, etc.

  • Haemophilus influenzae type b conjugate vaccine, meningococcal vaccines and pneumococcal vaccines become national standards in China.
  • High Technical Level

    ysb88会员登录网址-易胜博登陆-易胜博最新地址 Technology:
    - Highly comparable to European and American MNCs.

     

    ysb88会员登录网址-易胜博登陆-易胜博最新地址 Line Equipment and Plant Facilities:
    - Highly comparable to European and American MNCs; 
    - Integration of automation and information technology;
    - Transformation from digital to advanced manufacturing and smart manufacturing;
    - Industry-leading level of laboratory and technology transfer capacity. 

    High Cost-Efficiency

    Low Construction Cost: 
    - Short construction period and low capital investment.

     

    Low Operating Cost: 
    - Cost control model for all processes, low-voltage load of plant facilities, and exploration of a "high-quality, cost-efficient, and sustainable" industrial development model. 

     

    High Output per Unit: 
    - High output per capita, high output per dose and high input-output ratio.

    International Fill and Finish Center

    In order to support Walvax’s internationalization strategy, we have invested more than USD46 million in building an international fill and finish center with 5000 square meters. There are 4 packaging lines, and each line can produce about 150,000 doses per batch. Meanwhile, 3 packaging lines can meet the need in different sizes, and the annual capacity is about 100 million doses.


    In this center, the preparation, filling, lyophilization, visual inspection and packaging of RTF products are completed. At the same time, the center is equipped with integrated information systems such as modern storage management, laboratory information management and environment monitoring, which will ensure that the products meet the domestic and foreign requirements of quality management throughout the whole production cycle.


    The international fill and finish center was built to the GMP standards of China,Eu,WHO,PICs and ISPE. It adopted state-of-the-art production equipment and automatic control system, established standardized data center which mainly carries operation systems related to production quality such as integrated warehouse management system (WMS), manufacturing execution system (MES), laboratory information management system (LIMS), etc. Through the data collected from such systems, the information management of the entire process of vaccine production from raw material procurement to production, sales, and distribution are realized, ensuring that production fully meets quality requirements. Upon its completion, the center will be the most advanced intelligent manufacturing center in China.


    After the international fill and finish center is qualified by WHO PQ team, Walvax will become a world-class, advanced vaccine production base, participating in international procurement and becoming a supplier of large purchase by international organizations.

    46.6 / million

    USD46.6 million spent in the international fill and finish center

    5000 / m²

    5000 square meters of land area

    150,000 / doses

    150,000 doses per day per packing line

    100 / million

    100 million doses of annual capacity for bacterial vaccines